Effectiveness of golimumab in patients with ulcerative colitis: results of a real-life study in Switzerland.

Publikation

Effectiveness of golimumab in patients with ulcerative colitis: results of a real-life study in Switzerland.

Wissenschaftlicher Artikel/Review - 09.02.2022

Perrig Kathrin, Krupka Niklas, Jordi Sebastian Bruno Ulrich, Rossel Jean-Benoit, Biedermann Luc, Greuter Thomas, Schreiner Philipp, Vavricka Stephan R, Juillerat Pascal, Burri Emanuel, Zimmermann Dorothee, Maillard Michel H, Sulz Michael Christian, Brand Stephan, Rogler Gerhard, Misselwitz Benjamin

Zitation

Perrig K, Krupka N, Jordi S, Rossel J, Biedermann L, Greuter T, Schreiner P, Vavricka S, Juillerat P, Burri E, Zimmermann D, Maillard M, Sulz M, Brand S, Rogler G, Misselwitz B. Effectiveness of golimumab in patients with ulcerative colitis: results of a real-life study in Switzerland. Therap Adv Gastroenterol 2022; 15:17562848221074188.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Therap Adv Gastroenterol 2022; 15

Veröffentlichungsdatum

09.02.2022

ISSN (Druck)

1756-283X

Seiten

17562848221074188

Kurzbeschreibung/Zielsetzung

Tumor necrosis factor (TNF) inhibitors have improved treatment of ulcerative colitis (UC), but loss of response remains a frequent problem. The anti-TNF agent, golimumab, was approved in Switzerland for the treatment of UC in 2014. This study aims to summarize the experience of golimumab in a real-world setting in Switzerland.